publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
microbiolog
respiratori
system
infect
http
dx
mucos
epithelium
nasopharynx
wellrecogn
primari
site
bacteri
colonis
includ
opaqu
transpar
phenotyp
pneumococcu
pneumococcu
travers
lung
upon
aspir
start
adher
alveolar
type
ii
cell
initi
bacteri
infect
progress
pneumonia
occur
rapidli
preexist
respiratori
viral
infect
increas
bacteri
adher
facilit
virus
cytokin
differ
stage
pneumococc
pneumonia
well
known
first
stage
character
bulg
engorg
due
bacteri
presenc
serou
exud
alveoli
provid
nutrient
bacteria
facilit
infect
lung
next
stage
intens
inflammatori
reaction
involv
leakag
erythrocyt
alveoli
red
hepatis
follow
migrat
leukocyt
consolid
area
gray
hepatis
surfac
phagocytosi
leukocyt
due
intact
immun
system
host
normal
typespecif
antibodi
polymorphonuclear
leukocyt
phagocytis
pneumococci
lung
return
normal
state
howev
patient
compromis
immun
system
certain
complement
defici
hypogammaglobulinemia
absenc
typespecif
antibodi
bacteremia
occur
pneumococcu
virul
factor
mostli
cell
wall
compon
peptidoglycan
techoic
acid
protein
pneumolysin
induc
inflamm
caus
subsequ
tissu
damag
sinc
earli
lrti
caus
pneumonia
certain
develop
countri
ghana
south
africa
report
case
children
less
year
age
per
popul
adult
per
year
remain
equival
rate
even
decad
later
incid
pneumonia
children
less
year
age
higher
region
southeast
asia
africa
western
pacif
countri
comparison
develop
countri
like
america
europ
recent
incid
childhood
pneumonia
estim
million
global
progress
sever
diseas
vaccin
mortal
children
year
age
risk
factor
childhood
pneumonia
especi
develop
countri
includ
nutrit
defici
lack
breastfeed
indoor
air
pollut
due
passiv
smoke
hiv
infect
substandard
hous
live
condit
etiolog
agent
caus
pneumonia
includ
bacteria
respiratori
virus
certain
vaccin
studi
indic
predomin
bacteri
agent
caus
pneumonia
pneumonia
result
almost
sever
case
mortal
follow
h
influenza
account
sever
case
death
influenza
viru
remain
domin
viral
etiolog
agent
respons
sever
case
death
pneumonia
also
wellrecogn
caus
communityacquir
pneumonia
cap
children
lower
fatal
rate
addit
etiolog
agent
bacteria
staphylococcu
aureu
klebsiella
pneumonia
respiratori
virus
rsv
rhinoviru
human
metapneumoviru
human
bocaviru
parainfluenza
virus
commonli
identifi
agent
contribut
burden
childhood
pneumonia
communityacquir
pneumonia
cap
increas
health
problem
third
common
reason
hospit
adult
especi
elderli
age
year
preval
cap
report
case
per
popul
increas
year
old
year
old
year
old
sever
predispos
factor
impair
immun
lung
function
dysfunct
nasal
mucociliari
clearanc
lung
heart
diseas
smoke
identifi
independ
predictor
cap
adult
elderli
certain
studi
report
pneumonia
legionella
speci
h
influenza
moraxella
catarrhali
aureu
predomin
pathogen
cap
although
role
respiratori
virus
wellrecogn
cap
children
infant
well
understood
adult
elderli
still
unclear
whether
viru
caus
pneumonia
whether
viru
act
conjunct
respiratori
pathogen
one
studi
report
respiratori
virus
influenza
viru
rsv
adenoviru
rhinoviru
commonli
isol
part
coinfect
especi
pneumonia
thu
viral
agent
adult
cap
often
seem
part
mix
infect
usual
pneumonia
copathogen
world
health
organis
recommend
routin
childhood
immun
program
includ
vaccin
offer
protect
variou
respiratori
diseas
pneumonia
influenza
flu
measl
pertrussi
haemophilu
influenza
type
b
hib
vaccin
pneumococc
conjug
vaccin
increasingli
avail
develop
well
develop
countri
especi
pneumococc
conjug
vaccin
shown
effect
reduc
incid
sever
pneumonia
lower
respiratori
infect
children
current
three
vaccin
childhood
routin
immun
schedul
measl
hib
pneumococc
conjug
vaccin
wellrecogn
reduc
childhood
mortal
relat
pneumonia
vaccin
remain
primari
prevent
strategi
pneumonia
includ
cap
elderli
hib
vaccin
proven
effici
invas
mening
bacteremia
noninvas
pneumonia
caus
h
influenza
type
b
impress
effici
result
introduct
addit
hib
vaccin
worldwid
nation
immun
program
result
signific
reduct
vaccin
gap
develop
develop
countri
recent
review
sever
random
control
trial
differ
develop
countri
indic
signific
reduct
sever
pneumonia
pneumoniaassoci
mortal
reduct
radiolog
confirm
case
pneumonia
base
prevent
approach
pneumonia
pneumoniarel
mortal
effect
vaccin
certain
modelingbas
studi
estim
implement
present
annual
rate
increas
develop
countri
vaccin
could
save
pneumonia
death
cost
save
us
billion
high
coverag
hib
vaccin
immun
children
less
year
age
could
reduc
childhood
pneumonia
result
decreas
incid
sever
pneumonia
polysaccharid
vaccin
proteinconjug
polysaccharid
vaccin
two
vaccin
offer
protect
pneumococc
diseas
replac
conjug
vaccin
polysaccharid
vaccin
ppv
tcell
independ
boost
immunolog
memori
immun
offer
may
last
long
time
reason
vaccin
offer
infant
age
year
age
provid
children
age
year
elderli
peopl
risk
year
age
develop
pneumonia
contrast
conjug
vaccin
stimul
tcell
depend
respons
effect
infant
children
year
age
differ
pneumococc
vaccin
serotyp
cover
conjug
protein
use
mention
tabl
offer
children
age
week
year
age
wherea
given
children
age
week
year
adult
age
year
age
sinc
introduct
vaccin
efficaci
invas
mening
pneumonia
otiti
media
well
document
subsequ
vaccin
also
demonstr
compar
immunogen
sever
clinic
trial
although
cover
serotyp
pneumonia
recommend
adult
age
year
age
effect
reduc
invas
pneumococc
diseas
remain
uncertain
equal
greater
immunogen
greater
immunolog
memori
use
recommend
adult
addit
particularli
elderli
high
risk
individu
addit
newer
pcv
shown
reduc
number
healthi
carrier
pathogen
commun
herd
immun
unvaccin
peopl
protect
pathogen
sinc
introduct
pcv
part
herd
immun
incid
invas
pneumococc
diseas
shown
declin
almost
among
vaccin
children
year
age
adult
age
year
elderli
age
year
age
previous
vaccin
classif
antibiot
base
cellular
compon
affect
well
whether
induc
cell
death
bactericid
inhibit
cell
growth
bacteriostat
antibioticmedi
cell
death
complex
process
involv
physic
interact
drug
molecul
bacterialspecif
target
andor
modul
affect
bacterium
biochem
molecular
ultrastructur
level
fig
summar
differ
drug
target
mechan
action
variou
antimicrobi
inhibit
cell
wall
synthesi
inhibit
protein
synthesi
injuri
cytoplasm
membran
inhibit
nucleic
acid
synthesi
replic
dna
synthesi
cell
divis
wellrecogn
process
involv
modul
chromosom
supercoil
topoisomerasecatalyz
strand
breakag
rejoin
reaction
antimicrobi
quinolon
target
enzym
like
dna
gyras
topoisomeras
ii
topoisomeras
iv
topoiv
requir
bacteri
dna
synthesi
replic
prevent
dna
strand
rejoin
peptidoglycan
coval
crosslink
polym
matrix
compos
peptidelink
nacetyl
hexosamin
main
compon
bacteri
cell
wall
contribut
toward
structur
integr
bacteri
cell
peptidoglycan
layer
maintain
activ
transglycosylas
transpeptidas
enzym
add
disaccharid
pentapeptid
extend
glycan
strand
exist
peptidoglycan
molecul
crosslink
adjac
peptid
strand
immatur
peptidoglycan
unit
respect
glycopeptid
among
class
antibiot
interfer
cell
wall
biosynthesi
result
chang
bacteri
cell
shape
size
induct
cellular
stress
respons
lead
bacteri
cell
lysi
process
protein
synthesi
via
mrna
translat
involv
ribosom
compos
two
major
compon
subunit
drug
inhibit
protein
synthesi
divid
two
subclass
inhibitor
inhibitor
ribosom
inhibitor
includ
macrolid
lincosamid
streptogramin
amphenicol
oxazolidinon
class
antibiot
inhibitor
includ
tetracyclin
aminocyclitol
famili
antibiot
mortal
caus
due
pneumonia
avoid
costeffect
lifesav
treatment
antibiot
bacteri
pneumonia
therebi
significantli
increas
patient
chanc
surviv
pneumonia
manag
strategi
use
appropri
antibiot
support
care
includ
oxygen
system
remain
effect
cornerston
treatment
manag
children
suffer
pneumonia
integr
manag
childhood
ill
program
consist
report
reduct
childhood
mortal
rate
approxim
certain
commun
base
manag
strategi
report
decreas
mortal
due
usag
oral
antibiot
amoxicillin
four
type
antibiot
recommend
children
year
age
treatment
pneumonia
cotrimoxazol
amoxicillin
cephalosporin
macrolid
oral
amoxicillin
mgkgdose
use
day
nonsever
pneumonia
day
children
sever
pneumonia
sever
pneumonia
first
line
treatment
often
parenter
ampicillin
penicillin
gentamicin
follow
ceftriaxon
first
line
treatment
effect
variou
random
control
studi
cochran
databas
system
review
shown
multitud
avail
treatment
pneumonia
children
cefpodoxim
prove
effect
amoxicillin
amoxicillin
effect
chloramphenicol
amoxicillin
effect
altern
cotrimoxazol
cap
patient
coamoxyclavulan
acid
cefpodoxim
altern
secondlin
drug
choic
penicillinampicillin
plu
gentamicin
effect
chloramphenicol
children
hospit
sever
cap
pediatr
studi
suscept
pneumonia
isol
includ
serotyp
use
antibiot
secondand
thirdgener
cephalosporin
show
signific
efficaci
isol
clindamycin
suscept
levofloxacin
ceftriaxon
american
thorac
societi
european
respiratori
societi
recommend
hospit
patient
cap
prefer
treat
respiratori
fluoroquinolon
combin
therapi
macrolid
success
rate
incorpor
fluoroquninolon
combin
macrolid
base
clinic
bacteriolog
radiolog
examin
rang
vancomycin
clindamycin
base
local
suscept
data
also
provid
addit
therapi
clinic
laboratori
radiolog
characterist
consist
infect
caus
aureu
although
nonsever
sever
cap
manag
mani
antimicrobi
result
variou
studi
develop
countri
compar
differ
type
antibiot
need
studi
larger
clinic
trial
better
manag
pneumonia
develop
countri
anoth
major
health
concern
continu
rise
antibiot
resist
approxim
isol
resist
macrolid
includ
erythromycin
azithromycin
clarithromycin
introduct
inclus
hib
vaccin
past
year
result
almost
complet
elimin
h
influenza
children
therefor
consid
pathogen
cap
nontyp
h
influenza
also
consid
pathogen
pediatr
pneumonia
unless
detect
lung
diseas
copd
detect
true
pathogen
cap
oral
amoxicillin
consid
effect
neg
strain
produc
strain
amoxicillinclavulan
cefuroxim
cefdinir
cefixim
cefpodoxim
consid
effect
therapi
children
allerg
oral
agent
given
fluoroquinolon
although
infrequ
caus
cap
group
streptococcu
may
caus
sever
necrot
pneumonia
penicillin
g
dosag
ukgday
divid
dose
use
treat
patient
suffer
cap
due
group
streptococcu
macrolid
resist
greater
streptococc
infect
along
lower
toler
tissu
erythromycin
macrolid
administ
aureu
capabl
caus
pneumonia
usual
methicillinsensit
treat
either
stabl
penicillin
oxacillin
nafcillin
firstgener
cephalosporin
like
cefazolin
communityassoci
methicillinresist
aureu
mrsa
repres
clinic
isol
region
unit
state
shown
suscept
vancomycin
clindamycin
linezolid
howev
children
intoler
vancomycin
clindamycin
could
treat
linezolid
howev
sever
advers
effect
includ
suppress
platelet
neutrophil
nerv
injuri
mean
drug
use
caution
situat
mycoplasma
pneumonia
chlamydophila
pneumonia
signific
consider
upon
diagnost
evalu
empir
combin
therapi
macrolid
antibiot
consid
children
moder
sever
cap
consist
influenza
viru
infect
widespread
local
circul
influenza
virus
administ
influenza
antivir
therapi
suscept
strain
influenza
viru
commonli
treat
adamantan
neuraminidas
inhibitor
occurr
genet
variat
highli
substanti
among
influenza
strain
resist
either
class
antivir
agent
may
develop
quickli
howev
dosag
antivir
agent
current
recommend
season
influenza
develop
fulli
suscept
strain
evalu
clinic
trial
mandat
requir
treatment
within
day
onset
symptom
earli
antivir
treatment
shown
provid
maxim
benefit
treatment
delay
confirm
posit
influenza
test
result
neg
result
influenza
diagnost
test
especi
rapid
antigen
test
conclus
exclud
influenza
diseas
therefor
treatment
h
symptomat
infect
may
still
provid
clinic
benefit
sever
diseas
efficaci
ribavirin
treatment
rsv
cap
infant
debat
certain
vitro
studi
shown
activ
ribavirin
rsv
usag
rsv
infect
routin
recommend
manag
lower
respiratori
tract
diseas
high
cost
aerosol
administr
possibl
toxic
effect
among
healthcar
provid
palivizumab
synagi
humanis
murin
monoclon
antibodi
anoth
effect
prophylaxi
rsv
infect
administ
intramuscularli
although
parainfluenza
viru
adenoviru
metapneumoviru
rhinoviru
coronaviru
bocaviru
associ
pediatr
cap
prospect
control
studi
antivir
therapi
virus
sinc
introduct
penicillin
first
choic
treat
pneumococc
pneumonia
earli
infant
children
success
treat
amoxicillin
mgkgday
divid
equal
dose
suscept
natur
strain
time
resist
commonli
use
antibiot
pose
major
problem
concern
health
practition
choos
empir
therapi
bacteri
pneumonia
larg
geograph
variat
indic
differ
resist
pattern
widespread
pneumococc
resist
penicillin
dosag
increas
mgkgday
given
twice
daili
treat
children
acut
otiti
media
recent
review
highlight
advanc
understand
variou
mechan
bacteria
acquir
resist
antibiot
prevent
access
differ
drug
target
modul
inactiv
antibiot
introduct
pneumococc
conjug
vaccin
chang
antimicrobi
usag
significantli
alter
resist
pattern
pneumonia
decreas
degre
penicillin
resist
prompt
decreas
amoxicillin
dosag
compar
administ
prevaccin
era
last
decad
certain
multicentr
clinic
trial
studi
report
signific
decreas
suscept
rate
commonli
use
antibiot
amoxicillinclavulant
penicillin
ceftriaxon
respect
suscept
rate
macrolid
erythromycin
clindamycin
also
report
decreas
respect
recent
increas
resist
macrolid
report
sever
european
countri
includ
unit
kingdom
surveil
studi
involv
clinic
isol
report
around
increas
rate
ampicillin
trimethoprimsulfamethoxazol
resist
h
influenza
respect
antibiot
ceftarolin
ceftriaxon
amoxicillinclavulant
levofloxacin
show
suscept
studi
also
show
increas
resist
penicillin
toward
catarrhali
preval
known
reduc
suscept
penicillin
resist
macrolid
pneumonia
children
adult
cap
increasingli
emerg
countri
like
japan
franc
denmark
unit
state
china
rate
high
japan
china
europ
unit
state
communityacquir
mrsa
although
primarili
associ
skin
soft
tissu
infect
recogn
caus
invas
infect
includ
cap
almost
mortal
rate
report
unit
state
europ
certain
way
resist
antimicrobi
minim
limit
exposur
antibiot
whenev
possibl
limit
spectrum
usag
antimicrobi
specif
requir
treat
identifi
pathogen
use
proper
dosag
antimicrobi
achiev
minim
effect
concentr
site
infect
treatment
shortest
effect
durat
minim
exposur
pathogen
normal
microbiota
antimicrobi
minim
select
resist
increas
incid
antimicrobi
resist
remain
one
greatest
challeng
emerg
bacteri
infect
result
bacteria
essenti
untreat
current
avail
treatment
option
result
newer
antimicrobi
novel
mode
action
multidrug
resist
strain
develop
recent
review
highlight
combin
drug
offer
synergist
antagonist
drug
interact
drug
interact
provid
opportun
discoveri
newer
drug
recent
year
avail
new
antimicrobi
human
consumpt
lower
recent
past
new
class
antimicrobi
develop
sinc
introduct
nalidix
acid
linezolid
avail
antimicrobi
recent
year
mostli
result
modif
exist
molecul
one
reason
develop
new
antimicrobi
agent
expens
time
consum
research
develop
infect
drug
take
around
year
cost
around
us
million
addit
cost
bring
new
drug
market
strong
need
newer
unexploit
target
strategi
next
gener
antimicrobi
drug
drug
resist
emerg
pathogen
new
antimicrobi
agent
clinic
develop
stage
list
tabl
new
antibiot
shown
promis
result
treatment
pneumonia
cap
follow
ceftarolin
fifth
gener
cephalosporin
known
bind
penicillinbind
protein
prevent
synthesi
bacteri
cell
wall
novel
broadspectrum
antibiot
effect
mrsa
penicillin
cephalosporin
resist
pneumonia
vancomycinintermedi
aureu
visa
vancomycinresist
aureu
vrsa
also
activ
mani
gramneg
pathogen
inact
extendedspectrum
esbl
produc
bacteria
approv
treatment
cap
differ
random
doubleblind
multicentr
trial
demonstr
efficaci
clinic
cure
safeti
ceftarolin
intraven
mg
twice
daili
treatment
cap
ceftobiprol
anoth
newer
cephalosporin
broadspectrum
activ
mrsa
penicillinresist
pneumonia
p
aeruginosa
enterococci
random
trial
consist
hospit
adult
sever
cap
administ
ceftobiprol
intraven
mg
min
everi
h
show
signific
differ
treatment
group
found
advers
event
includ
nausea
vomit
patient
telavancin
semisynthet
lipoglycopeptid
deriv
vancomycin
known
disrupt
peptidoglycan
synthesi
alter
cell
membran
function
use
treat
complic
skin
infect
caus
aureu
hospitalacquir
bacteri
pneumonia
includ
ventilatorassoci
bacteri
pneumonia
caus
suscept
isol
aureu
telithromycin
first
ketolid
enter
clinic
use
treatment
cap
chronic
bronchiti
acut
sinus
telithromycin
protein
synthesi
inhibitor
block
progress
grow
polypeptid
chain
bind
subunit
bacteri
ribosom
exhibit
time
higher
affin
subunit
subunit
erythromycin
addit
telithromycin
strongli
bind
simultan
two
domain
subunit
ribosom
subunit
older
macrolid
bind
one
domain
weakli
second
domain
vitro
studi
show
activ
telithromycin
pneumonia
compar
clarithromycin
azithromycin
found
maintain
activ
macrolideresist
strain
pneumonia
pyogen
formul
mg
tablet
oral
administr
good
absorpt
bioavail
howev
fda
withdrew
approv
treatment
cap
due
safeti
concern
involv
hepatotox
myasthenia
gravi
exacerb
visual
disturb
cethromycin
deriv
erythromycin
link
aromat
ring
bind
strongli
ribosom
subunit
inhibit
bacteri
protein
synthesi
cethromycin
display
vitro
activ
streptococci
includ
strain
pneumonia
resist
penicillin
macrolid
activ
greater
telithromycin
macrolideresist
streptococci
potent
macrolid
fluoroquinolon
penicillinresist
streptococci
also
display
compar
vitro
activ
azithromycin
respiratori
gramneg
organ
includ
h
influenza
catarrhali
shown
potent
erythromycin
clarithromycin
less
potent
fluoroquinolon
h
influenza
show
similar
potenc
catarrhali
solithromycin
new
macrolid
first
fluoroketolid
clinic
develop
proven
activ
macrolideresist
bacteria
solithromycin
develop
intraven
oral
formul
treatment
cap
allow
oral
therapi
ivtoor
stepdown
therapi
appropri
patient
recent
multicentr
doubleblind
random
phase
ii
studi
consist
patient
moder
sever
cap
administ
oral
solithromycin
load
dose
mg
mainten
day
show
efficaci
compar
levofloxacin
treatment
cap
favor
safeti
toler
profil
nemonoxacin
novel
nonfluorin
quinolon
proven
vitro
vivo
activ
cap
pathogen
includ
multidrug
resist
pneumonia
random
multicentr
trial
consist
cap
patient
treat
oral
administr
nemonoxacin
day
show
remark
clinic
bacteriolog
success
rate
compar
tolevofloxacin
therapi
recent
comprehens
review
well
document
data
avail
pharmacodynam
pharmacokinet
clinic
treatment
studi
antimicrobi
agent
zabofloxacin
develop
new
fluoroquinolon
antibiot
potent
select
inhibitor
essenti
bacteri
type
ii
topoisomeras
topoisomeras
iv
indic
communityacquir
respiratori
infect
due
gramposit
bacteria
two
dose
regimen
zabofloxacin
zabofloxacin
hydrochlorid
mg
capsul
andzabofloxacin
aspart
mg
tablet
welltoler
advers
effect
two
novel
fluoroquinolon
develop
treatment
bacteri
pathogen
respons
respiratori
infect
includ
cap
skin
infect
agent
demonstr
increas
potenc
compar
market
fluoroquinolon
thu
encourag
clinic
develop
recent
semisynthet
pleuromutilin
antibiot
excel
antibacteri
activ
skin
pathogen
aureu
streptococci
viridan
streptococci
enterococcu
faecium
well
respiratori
pathogen
activ
respiratori
pathogen
also
confirm
variou
murin
model
infect
use
pneumonia
h
influenza
aureu
mrsa
nosocomi
communityassoci
better
drug
penetr
strongli
support
potenti
use
treatment
bacteri
respiratori
tract
infect
although
wide
varieti
clinic
efficaci
antibiot
use
today
develop
bacteri
resist
render
less
effect
bacteriostat
act
either
protein
cell
wall
synthesi
inhibit
research
need
design
novel
antibacteri
agent
new
target
one
approach
could
design
antibiot
use
novel
drug
target
bacteri
enzym
synthas
iii
requir
fatti
acid
biosynthesi
platensimycin
one
drug
undergo
preclin
trial
known
block
enzym
involv
biosynthesi
essenti
fatti
acid
gramposit
bacteria
potent
antibacteri
activ
gramposit
bacteria
includ
multidrug
resist
staphylococci
enterococci
anoth
approach
worth
investig
could
combin
antibiot
natur
occur
enzym
gastrointestin
microbiota
enzym
shown
hydrolys
variou
antibiot
includ
penicillin
ampicillin
piperacillin
protein
kda
one
exampl
structur
function
similar
enzym
emerg
resist
microb
significantli
reduc
take
advantag
combin
natur
occur
hydrolysi
antibacteri
drug
current
avail
drug
phase
ii
trial
treatment
seriou
respiratori
infect
incorpor
treatment
product
ampicillin
show
chang
gut
microbiota
compar
chang
patient
treat
ampicillin
alon
apart
antimicrobi
strategi
involv
immunomodul
inflammatori
respons
target
pattern
recognit
receptor
signal
corticosteroid
complement
inhibitor
etc
improv
pulmonari
barrier
function
use
adrenomedullin
angiopoietin
etc
pneumonia
associ
complic
could
add
new
dimens
provid
better
therapeut
patient
despit
great
advanc
manag
prevent
approach
pneumonia
still
remain
major
burden
mortal
morbid
young
children
elderli
especi
develop
underdevelop
countri
prevent
mean
vaccin
critic
reduc
pneumonia
mortal
children
year
age
effect
antibiot
therapi
import
elderli
widespread
emerg
antimicrobi
resist
wellrecogn
caus
ineffect
larg
number
current
use
antimicrobi
although
numer
effort
made
combat
newer
target
need
identifi
gener
next
level
effect
antimicrobi
addit
complet
understand
variou
aspect
drug
resist
microb
essenti
assist
us
design
better
target
help
us
discov
new
antibacteri
drug
near
futur
next
challeng
identifi
newer
agent
treatment
multidrug
resist
pathogen
emerg
rapid
rate
constant
unpredict
natur
pneumococc
pathogen
outpac
technolog
drug
develop
strategi
therefor
critic
research
pharmaceut
compani
govern
fund
bodi
continu
make
progress
develop
new
strategi
antimicrobi
toward
respiratori
infect
includ
pneumonia
